Sandoz AG v Bayer Intellectual Property GmbH

Link copied
Case Copied 75 min read

FEDERAL COURT OF AUSTRALIA

Sandoz AG v Bayer Intellectual Property GmbH [2023] FCA 1321  

File number(s): VID 683 of 2021
Judgment of: ROFE J
Date of judgment: 2 November 2023
Catchwords:

PATENTS – infringement – where invention claimed is an oral tablet comprising the compound rivaroxaban
“in hydrophilized form” and the use of that drug for the prophylaxis and/or treatment of a thromboembolic disease – construction of patent – meaning of “in hydrophilized form” and “hydrophilization” – whether pieces of prior art referred to in the specification are incorporated by reference

PATENTS – validity – challenge to best method – incorrect PCT reference – principles regarding rectification of mistakes in patent specifications

PATENTS – validity – lack of inventive step – consideration of s 7(3) of the Patents Act 1990 (Cth) – whether two pieces of prior art are s 7(3) documents – consideration of common general knowledge – whether invention was obvious in light of prior art – whether person skilled in the art could engage in pre-clinical testing and Phase I, II and III clinical trials without the identity or structure of the relevant compound – drug development journey for the compound was “voyage of discovery” not the undertaking of “routine steps

PATENTS – validity – clarity – whether “plasma concentration half life” is sufficiently clear

PATENTS – application to amend – typographical error – whether unreasonable delay – application granted under s 105 of the Act

Legislation:

Federal Court of Australia Act 1976 (Cth)

Patents Act1990 (Cth)

Cases cited:

Adhesives Pty Ltd v Aktieselskabet Dansk Gaerings-Industri (1935) 55 CLR 523

Airco Fasteners Pty Ltd v Illinois Tool Works Inc [2023] FCAFC 7

Aktiebolaget Hässle v Alphapharm Pty Ltd (2002) 212 CLR 411

AMP Inc v Utilux Pty Ltd [1971] 45 ALJR 123

Apotex Pty Ltd v AstraZeneca AB (No 4) (2013) 100 IPR 285

Apotex Pty Ltd v ICOS Corporation (No 3) (2018) 135 IPR 13

Apotex Pty Ltd v Warner-Lambert Co LLC (No 2) (2016) 122 IPR 17

AstraZeneca AB v Apotex Pty Ltd (2014) 107 IPR 177

AstraZeneca AB v Apotex Pty Ltd (2015) 257 CLR 356

Austal Ships Sales Pty Ltd v Stena Rederi Aktiebolag (2008) 77 IPR 229

Austal ShipsSales v Stena Rederi Aktiebolag (2008) 77 IPR 229

Australian Mud Company v Globaltech Corporation Pty Ltd (2018) 138 IPR 33

Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd (2012) 99 IPR 59

Becton Dickinson Pty Ltd v B Braun Melsungen AG [2018] FCA 1692

BlueScopeSteel Ltd v Dongkuk Steel Mill Co, Ltd (No 2) (2019) 152 IPR 195

Boehringer Ingelheim Animal Health USA Inc v Intervet International BV (2022) 166 IPR 468

Commissioner of Patents v Emperor Sports Pty Ltd (2006) 67 IPR 488

CSL Ltd v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) (2010) 89 IPR 288

Davies v Lazer Safe Pty Ltd [2019] FCAFC 65

Eli Lilly & Co v Pfizer Overseas Pharmaceuticals (2005) 64 IPR 506

Eli Lilly and Co Ltd v Apotex Pty Ltd (2013) 100…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Sandoz AG v Bayer Intellectual Property GmbH and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2023] FCA 1321
Decision Date

CaseChat Overview and Summary

Sandoz AG and Sandoz Pty Ltd (together, the Applicants) brought proceedings against Bayer Intellectual Property GmbH, Bayer AG and Bayer HealthCare LLC (together, Bayer) for, inter alia, a declaration of non-infringement of Bayer’s Australian Patent AU2004305226 (the 226 Patent) and Australian Patent AU2007206613 (the 613 Patent). The Applicants also sought to amend the 613 Patent. Bayer filed a cross-claim for, inter alia, a declaration of infringement of the 226 Patent and the 613 Patent, an injunction to prevent the Applicants’ threatened infringement of the 613 Patent and an amendment to the 613 Patent. The Applicants challenged the validity of the 226 Patent and the 613 Patent on various grounds. The Applicants also challenged the clarity of certain terms in the 613 Patent. Bayer defended the proceedings. The Applicants sought to amend the 613 Patent to correct a typographical error. The Court was required to determine the validity of the 226 Patent and the 613 Patent, and whether the Applicants’ products infringed the 226 Patent and the 613 Patent. The Court was also required to determine whether the Applicants’ application to amend the 613 Patent should be granted. The Court held that both the 226 Patent and the 613 Patent were valid. The Court held that the Applicants’ products did not infringe the 226 Patent. The Court held that the Applicants’ products would infringe the 613 Patent if it was not amended. The Court held that the Applicants’ application to amend the 613 Patent should be granted. The Court held that Bayer was entitled to an injunction to prevent the Applicants’ threatened infringement of the 613 Patent. The Court dismissed the Applicants’ application and accepted Bayer’s cross-claim in part. The Court made orders to reflect these reasons.

Orders

Orders of the court

1. The First and Second Applicants’ application be dismissed.

2. The First and Second Cross-Claimants’ cross-claim be allowed in-part.

3. The Cross-Respondent, whether by itself, its directors, officers, servants, agents, Related Bodies Corporate (as defined in the Corporations Act 2001 (Cth)), Associated Entities (as defined in the Corporations Act) or howsoever otherwise (together, Sandoz), during the term of the 613 Patent be restrained from infringing claims 3 and 4 of the 613 Patent, including (without limitation) by engaging in the following acts within the patent area (as that term is defined in the Patents Act 1990 (Cth)), without the licence or authority of the Cross-Claimant:

(a) importing, selling, supplying or otherwise disposing of the Sandoz Rivaroxaban Products;

(b) offering to sell, supply or otherwise dispose of the Sandoz Rivaroxaban Products;

(c) authorising other persons to use the Sandoz Rivaroxaban Products or engage in any of the acts described in subpara (a) and (b) above;

(d) procuring or inducing, whether by instructions or otherwise, any of the acts described in subpara (a) and (b) above; or

(e) otherwise infringing the 613 Patent.

4. The 613 Patent be amended in the manner described in the Annexure hereto.

5. The First Applicant and Second Applicant/Cross-Respondent pay the Respondent/Cross-Claimants’ costs of the application and the cross-claim with a 15% reduction for the Applicants succeeding on the meaning of “in hydrophilized form” issue. Such costs are to be taxed if not agreed.

6. The Cross-Claimants pay the costs of the amendment application.

7. If any party seeks a variation of the costs orders in paragraphs 5 and 6 above, it may, within seven days, file and serve a written submission (of no more than two pages) and any affidavit in support. In that event, the other party may file and serve a responding written submission (of no more than two pages) and any affidavit in support within a further seven days, and the issue of costs will be determined on the papers.

THE COURT CERTIFIES THAT:

8. Pursuant to s 19 of the Patents Act, the validity of each of the claims of the Australian Patent AU2004305226 entitled “Method for the production of a solid, orally applicable pharmaceutical composition” and the 613 Patent were questioned in this proceeding and found to be valid.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

ANNEXURE

Insert the number “7” immediately after the incomplete PCT number PCT/04/01289 and insert

the country code "EP" before the application date code of "04" on page 10, line 13 of the 613 Patent, as shown below.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

I will exercise my discretion to allow the amendment to the 613 Patent.13. CONCLUSION For the reasons given above, I find that both the 226 Patent and the 613 Patent are valid. Bayer accepts that, on my construction of the term “in hydrophilized form”, the Sandoz Rivaroxaban products do not infringe the claims of the 226 Patent. I will exercise my discretion to amend the 613 Patent in the form sought. I will also grant the injunction sought by Bayer to prevent Sandoz’s threatened infringement of the 613 Patent. Accordingly, I reject Sandoz’s application and accept Bayer’s cross-claim in part. I will make orders to reflect these reasons.

Ratio Decidendi

Legal Principle Established

Parenteral administration refers to administration other than by the GI tract (eg mouth), generally injection or infusion. Peripheral vascular disease refers to where the arteries develop atherosclerosis, which is the thickening or hardening of arteries caused by the build-up of plaque in the inner lining of an artery. Rupture of the plaque results in a highly thrombotic surface, resulting in blood clot formation. Permeability refers to the ability of an API to move across cell membranes such as those lining the GI system. Permeability encompasses passive movement (eg through or between the cells of the GI lining) and active movement (eg via transporters within the GI lining). Permeability is also affected by efflux transporters which restrict movement across the GI lining. Pharmacokinetics refers to the study of the time course of API in the body. The pharmacokinetic profile of an API depends on its:(a)absorption;(b)distribution;(c)metabolism; and(d)excretion.“Elimination” is the combination of metabolism and excretion. Pharmacokinetics is sometimes referred to as PK or by using the acronym ADME. Pharmacodynamics refers to the time course of the intensity of the pharmacological effect(s) that an API has in the body. Pharmacodynamics incorporates both (i) the therapeutic effect of the API (ie treating or improving the relevant condition) and (ii) any side effects caused by the API. Pharmacodynamics may be distinguished from pharmacokinetics in that pharmacodynamics describes how an API affects the body, whereas pharmacokinetics describes how the body affects an API. Pharmacodynamics is sometimes referred to as PD. Plasma refers to the liquid component of blood after it has undergone centrifugation to separate the cellular components such as red and white blood cells and platelets. Pre-formulation typically includes experimental, in vitro investigations into at least the stability, dissolution and solubility of the drug (in various potentially relevant biological and environmental conditions), its crystal form and polymorphism, as well as its compatibility with any excipients that might be selected for use in the formulations used in clinical trials. To assess such matters, particularly for potentially sold oral dosage forms, in vitro solubility and dissolution testing are often performed. Prothrombin time (PT) test is a clotting test that was used to measure the effects of warfarin treatment before the priority dates. It was known to respond to reductions in factors II, VII, IX and X during warfarin therapy. It was performed by adding thromboplastin (generally a phospholipid-protein tissue extract) and calcium to plasma, which has been treated with citrate, to prevent it from clotting. Pulmonary embolism occurs where there is a blockage of the pulmonary artery in the lung. Solubility refers to the maximum amount of a compound that will dissolve in a given volume of specified fluid at a particular temperature and pH. Solubility is distinct from dissolution, which refers to the rate at which particles dissolve in solution.